Is OrganiGram a Buy After Its Improved Q3 Results?

·4-min read
Is OrganiGram a Buy After Its Improved Q3 Results?

Canadian cannabis company OrganiGram Holdings (NASDAQ: OGI) hasn't been a great growth investment over the past year. OrganiGram highlighted impressive quarter-over-quarter revenue growth of 51% when it reported its third-quarter results. Net revenue of CA$20.3 million was up by 39% from the previous quarter.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting